Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) insider Dan Karlin sold 6,578 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $9.50, for a total value of $62,491.00. Following the completion of the sale, the insider now directly owns 358,452 shares in the company, valued at $3,405,294. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Mind Medicine (MindMed) Stock Down 3.7 %
Shares of MNMD opened at $9.50 on Thursday. The company has a current ratio of 3.22, a quick ratio of 3.22 and a debt-to-equity ratio of 0.18. The firm has a fifty day simple moving average of $5.99 and a two-hundred day simple moving average of $4.23. Mind Medicine has a 1-year low of $2.41 and a 1-year high of $11.10.
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11). On average, equities research analysts expect that Mind Medicine will post -1.7 EPS for the current year.
Institutional Investors Weigh In On Mind Medicine (MindMed)
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on MNMD shares. Canaccord Genuity Group started coverage on Mind Medicine (MindMed) in a research report on Tuesday, December 5th. They issued a “buy” rating and a $9.00 price objective on the stock. Royal Bank of Canada upped their price objective on Mind Medicine (MindMed) from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Mind Medicine (MindMed) in a research report on Thursday, March 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $24.83.
View Our Latest Stock Analysis on Mind Medicine (MindMed)
Mind Medicine (MindMed) Company Profile
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder.
Read More
- Five stocks we like better than Mind Medicine (MindMed)
- Investing In Automotive Stocks
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- ETF Screener: Uses and Step-by-Step Guide
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.